Generic Medicine Info
Severe heart disease, history of symptomatic arrhythmias, known or suspected QT prolongation, clinically significant bradycardia, electrolyte imbalance (e.g. hypokalaemia). Severe hepatic impairment. Concomitant use with macrolide antibiotics (e.g. erythromycin), systemic imidazole antifungals (e.g. ketoconazole), other agents that may prolong the QT interval (e.g. Class I and III antiarrhythmics).
Special Precautions
Mild to moderate hepatic impairment. Elderly. Pregnancy and lactation. Patient Counselling This medicine may cause drowsiness, if affected, do not drive or operate machinery.
Adverse Reactions
Significant: CNS depression; QT prolongation. Gastrointestinal disorders: Nausea, dry mouth, abdominal pain, dyspepsia, diarrhoea. General disorders and administration site conditions: Transient asthenia. Investigations: Increased weight. Metabolism and nutrition disorders: Increased appetite. Nervous system disorders: Headache, dizziness, transient drowsiness.
ATC Classification
R06AX25 - mizolastine ; Belongs to the class of other antihistamines for systemic use.
Disclaimer: This information is independently developed by CIMS based on mizolastine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in